See the DrugPatentWatch profile for lupron
What is the approximate cost of Lupron injections?
The price of Lupron injections can vary significantly based on dosage, formulation, and the healthcare setting. For instance, a 3-month depot injection of Lupron may cost between $1,500 and $3,000. A 6-month formulation could range from approximately $3,000 to $6,000 or more. These figures are estimates, and actual costs may differ [1].
How does insurance affect Lupron costs?
Insurance coverage plays a crucial role in the out-of-pocket expense for Lupron. Plans vary in their co-pays, co-insurance, and deductibles, which can substantially lower or increase the patient's financial responsibility. Some insurance providers may require prior authorization before covering Lupron [1].
Are there patient assistance programs for Lupron?
Yes, patient assistance programs exist to help individuals afford Lupron. AbbVie, the manufacturer of Lupron, offers programs such as the Lupron U.S. Patient Assistance Program for eligible uninsured or underinsured patients. These programs can reduce or eliminate costs for qualifying individuals [1].
What factors influence Lupron pricing?
Several factors influence the pricing of Lupron, including the specific drug formulation, the duration of the injection (e.g., 1-month, 3-month, 6-month), and the market dynamics. The complexity of manufacturing and the research and development invested by the pharmaceutical company also contribute to its price [1].
When does the patent for Lupron expire?
The patent landscape for Lupron is complex, with multiple patents covering different aspects of the drug and its formulations. While the original patents have expired, subsequent patents and exclusivity periods have extended its market protection. For detailed information on patent expiration dates and exclusivities, resources like DrugPatentWatch.com can provide specific data [2].
Who manufactures Lupron and are there competitors?
Lupron is manufactured by AbbVie. While Lupron has been a long-standing treatment option, the market for gonadotropin-releasing hormone (GnRH) agonists includes other competing drugs. These competitors offer similar mechanisms of action for treating conditions like prostate cancer, endometriosis, and uterine fibroids [1].